Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Achaogen Inc    AKAO

ACHAOGEN INC (AKAO)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/10/2018 10/11/2018 10/12/2018 10/15/2018 10/16/2018 Date
3.95(c) 3.84(c) 3.72(c) 3.75(c) 4.12 Last
536 971 593 142 566 204 743 745 359 381 Volume
-4.36% -2.78% -3.13% +0.81% +9.87% Change
More quotes
Financials (USD)
Sales 2018 14,8 M
EBIT 2018 -182 M
Net income 2018 -178 M
Finance 2018 319 M
Yield 2018 -
Sales 2019 46,5 M
EBIT 2019 -127 M
Net income 2019 -127 M
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales2018 -10,2x
Capi. / Sales2019 3,62x
Capitalization 168 M
More Financials
Company
Achaogen, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of antibacterial treatments for multi-drug resistant (MDR) gram-negative infections.It offers Plazomicin to treat bacterial illness, such as complicated urinary tract infection, blood... 
More about the company
Surperformance© ratings of Achaogen Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on ACHAOGEN INC
10/12MANAGEMENT TRACKS : Former Baxalta exec joins VisionGate; Carrick names Golumbes..
AQ
10/05ACHAOGEN : Highlights Multiple Plazomicin Presentations at IDWeek 2018
AQ
10/03Achaogen Highlights Multiple Plazomicin Presentations at IDWeek 2018
GL
09/21ACHAOGEN : Announces Multiple Plazomicin Presentations at IDWeek 2018
AQ
09/20ACHAOGEN : to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference
AQ
09/19Achaogen Announces Multiple Plazomicin Presentations at IDWeek 2018
GL
09/18Achaogen to Present at the 2018 Cantor Fitzgerald Global Healthcare Conferenc..
GL
09/17ACHAOGEN : Change in Directors or Principal Officers (form 8-K/A)
AQ
09/17ACHAOGEN : Gottlieb releases FDA's plan to combat antibiotic resistance, calls f..
AQ
09/04Achaogen Highlights Multiple Plazomicin Presentations at ESCMID/ASM 2018 Conf..
GL
More news
Sector news : Bio Therapeutic Drugs
07:30aSanofi's Dupixent Shows Positive Headline Results in Two Phase 3 Studies
DJ
10/11GILEAD SCIENCES : Allogene's Upsized IPO Prices at High End of Range
DJ
10/05ABBVIE : Receives Health Canada Approval of Orilissa for Endometriosis Pain Trea..
DJ
10/04J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 billion
RE
10/02GILEAD SCIENCES : Allogene Sets IPO at 16 Million Shares; Sees Pricing $16-$18
DJ
More sector news : Bio Therapeutic Drugs
Latest Tweets
10/13Achaogen $AKAO Raised to “Buy” at Zacks Investment Research  
10/13Achaogen Inc $AKAO Expected to Post Quarterly Sales of $4.05 Million  
10/11$RVNC: Revance Therapeutics appoints Tobin C. SChilke as CFO effective Novemb..
1
10/11Get the latest ratings for $CYBR $CPTA $AKAO $CVEO $NTNX in your inbox with M.. 
10/08Zacks: Brokerages Anticipate Achaogen Inc $AKAO to Announce -$0.96 Earnings P.. 
More tweets
Qtime:24
News from SeekingAlpha
10/11CONTRAFECT : A New Anti-Microbial Treatment Paradigm 
10/04Forensic Stock Selections For October - Positive Forensic Returns Averaging +.. 
10/03Antibiotic developers in the green on Paratek news 
09/28Key events next week - healthcare 
09/26HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am (09/26/2018) 
Chart ACHAOGEN INC
Duration : Period :
Achaogen Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ACHAOGEN INC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 15,3 $
Spread / Average Target 309%
EPS Revisions
Managers
NameTitle
Blake Wise Chief Executive Officer & Director
Bryan E. Roberts Chairman
Liz Bhatt Chief Operating & Business Officer
Zeryn Sarpangal Chief Financial & Accounting Officer
Kenneth J. Hillan Director & President-R&D
Sector and Competitors
1st jan.Capitalization (M$)
ACHAOGEN INC-65.08%168
GILEAD SCIENCES1.59%95 398
VERTEX PHARMACEUTICALS20.99%46 338
REGENERON PHARMACEUTICALS2.18%40 777
NEUROCRINE BIOSCIENCES, INC.41.84%10 086
SAREPTA THERAPEUTICS INC136.05%8 671